E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Type 1 diabetes, microalbuminuria or macroalbuminuria and mildly impaired kidney function. |
|
E.1.1.1 | Medical condition in easily understood language |
Type 1 diabetes and early signs of kidney complications |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Hormonal diseases [C19] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1. To obtain estimates of the distribution of the primary outcome (GFR decline) in the study population in order to properly power a future pivotal clinical trial.
|
|
E.2.2 | Secondary objectives of the trial |
2. To pilot study procedures, such as the run-in period, the allopurinol dosage adjustment algorithms, and the iohexol clearance GFR measurement.
3. To gather preliminary data about the efficacy of allopurinol in reducing GFR decline over 2 years. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• • Male or female T1D patients between 18 and 60 years of age.
• T1D diagnosed before age 35 and continuously treated with insulin within one year from diagnosis. If the onset was between ages 31 and 35, body mass index (BMI) will be required to be < 26 kg/m2 at the time of diagnosis;
• Duration of T1D ≥ 5 years;
• Presence of microalbuminuria or moderate macroalbuminuria (at least two out of three consecutive urinary albumin excretion rates [AER] or urinary albumin/creatinine ratios (ACR) measured during the preceding two years in the 30-1500 mg/24 hr or the 30-1500 mg/g range, respectively).
• Estimated GFR (based on serum creatinine and the CKD-EPI equation) between 35 and 109 ml/min/1.73 m2 at the screening visit.
• Measured GFR between 45 and 99 ml/min/1.73 m2 at the end of the run-in period;
• Serum UA ≥ 4.5 mg/dl at the screening visit.
• Willing to comply with schedule of events and protocol requirements.
|
|
E.4 | Principal exclusion criteria |
• • History of gout requiring uric acid lowering therapy or xanthinuria or other indications for uric acid lowering therapy such as cancer chemotherapy or extremely high serum uric acid values (≥12 mg/dl)
• Recurrent renal calculi.
• Use of urate-lowering agents within 3 months before enrollment.
• Current use of azathioprine, 6-mercaptopurine, didanosine, warfarin, tamoxifen, amoxicillin/ampicillin, or other drugs interacting with allopurinol.
• Known allergy to xanthine-oxidase inhibitors or iodine containing substances.
• HLA B*58:01 genotype (determined at the time of randomization) indicating increased risk of Stevens-Johnson syndrome in response to allopurinol.
• Renal transplant.
• Non-diabetic kidney disease as indicated by medical history and/or laboratory findings.
• SBP>160 or DBP >100 mmHg at screening or SBP>140 or DBP>90 mmHg at the end of the run-in period.
• Cancer treatment within two years before enrollment.
• History of clinically significant hepatic disease including hepatitis B or C and/or ALT (SGPT) >2.50 x ULN at screening;
• History of acquired immune deficiency syndrome or human immunodeficiency virus (HIV);
• Hemoglobin concentration <11 g/dL (males), <10 g/dL (females) at screening.
• Platelet count <100,000/mm3 at screening.
• History of alcohol or drug abuse in the past 12 months
• Breastfeeding or pregnancy or unwillingness to be on contraception.
• Poor mental function or any other reason to expect patient difficulty in complying with the requirements of the study.
• Serious pre-existing medical problems other than diabetes, e.g. congestive heart failure, pulmonary insufficiency.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
GFR at the end of the 2-year intervention measured by the plasma clearance of non-radioactive iohexol (iGFR) and adjusted for the GFR at baseline |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After 2 years study duration |
|
E.5.2 | Secondary end point(s) |
1. Estimated GFR (eGFR) time trajectory estimated from quarterly serum creatinine and cystatin C measurements using the CKD-EPI SCr and the CKD-EPI SCr-SCysC equations.
2. Time to doubling of baseline serum creatinine value or ESRD (eGFR ≤ 15 ml/min/1.73 m2).
3. Median urinary AER during the last three months of the intervention period, adjusted for the median urinary AER at baseline. Urinary AER will be determined in timed overnight urine collections brought by study participants to regular clinic visits, and expressed in g/minute and as urinary albumin creatinine ratios.
4. Time to fatal or non-fatal cardiovascular events, defined as the composite of CVD death (ICD-10 code I10 to I74.9), myocardial infarction, stroke, coronary artery bypass grafting, or percutaneous coronary intervention.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Throughout the duration of the study |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 2 |